Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus RENESE R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus RENESE R.
ALDORIL 15 vs RENESE-R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination